Tumor-infiltrating lymphocytes as easily accessible prognostic tool in adenocarcinoma of the colon.

Q3 Medicine Experimental oncology Pub Date : 2021-12-01 DOI:10.32471/exp-oncology.2312-8852.vol-43-no-4.16991

L Zakhartseva, B Shkurupii

{"title":"Tumor-infiltrating lymphocytes as easily accessible prognostic tool in adenocarcinoma of the colon.","authors":"L Zakhartseva, B Shkurupii","doi":"10.32471/exp-oncology.2312-8852.vol-43-no-4.16991","DOIUrl":null,"url":null,"abstract":"Aim: To determine the prognostic value of tumor-infiltrating lymphocytes (TILs) in colon adenocarcinomas.Materials and methods: The study was performed on 180 paraffin blocks of operation material from patients diagnosed with adenocarcinoma of the colon, treated at the Kyiv City Oncology Center in 2013-2018. TILs were counted on histological slides stained with hematoxylin-eosin. By TILs count percentage in tumor slides, the samples were divided into three groups: 0-9% TILs (n = 65); 10-39% TILs (n = 79); and > 40% TILs (n = 36).Results: Kaplan - Meyer estimate showed that the difference in overall survival between groups was significant (p = 0.001). Multivariate Cox's proportional hazard regression model analysis evidenced on significantly better overall survival rates in groups with moderate TILs percentage (hazard ratio 0.54, 95% CI 0.30-0.97, p = 0.042) and high TILs percentage (hazard ratio 0.36, 95% CI 0.13-0.99, p = 0.049), respectively, as compared with low TILs percentage group.Conclusion: TILs content can be considered as an independent prognostic factor for colon adenocarcinoma and used as an additional tool in routine practice of pathologists.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"43 4","pages":"331-335"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16991","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To determine the prognostic value of tumor-infiltrating lymphocytes (TILs) in colon adenocarcinomas.

Materials and methods: The study was performed on 180 paraffin blocks of operation material from patients diagnosed with adenocarcinoma of the colon, treated at the Kyiv City Oncology Center in 2013-2018. TILs were counted on histological slides stained with hematoxylin-eosin. By TILs count percentage in tumor slides, the samples were divided into three groups: 0-9% TILs (n = 65); 10-39% TILs (n = 79); and > 40% TILs (n = 36).

Results: Kaplan - Meyer estimate showed that the difference in overall survival between groups was significant (p = 0.001). Multivariate Cox's proportional hazard regression model analysis evidenced on significantly better overall survival rates in groups with moderate TILs percentage (hazard ratio 0.54, 95% CI 0.30-0.97, p = 0.042) and high TILs percentage (hazard ratio 0.36, 95% CI 0.13-0.99, p = 0.049), respectively, as compared with low TILs percentage group.

Conclusion: TILs content can be considered as an independent prognostic factor for colon adenocarcinoma and used as an additional tool in routine practice of pathologists.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤浸润淋巴细胞在结肠腺癌中作为易于获得的预后工具。

目的:探讨肿瘤浸润淋巴细胞(til)在结肠腺癌中的预后价值。材料和方法:研究对象为2013-2018年在基辅市肿瘤中心接受治疗的结肠腺癌患者的180块石蜡手术材料。在苏木精-伊红染色的组织学切片上计数TILs。根据TILs在肿瘤载玻片中的计数百分比将样本分为三组:0-9% TILs (n = 65);10-39% TILs (n = 79);> 40%的til (n = 36)。结果:Kaplan - Meyer估计显示两组间总生存率差异显著(p = 0.001)。多因素Cox比例风险回归模型分析表明，与低TILs百分比组相比，中等TILs百分比组(风险比0.54,95% CI 0.30-0.97, p = 0.042)和高TILs百分比组(风险比0.36,95% CI 0.13-0.99, p = 0.049)的总生存率显著提高。结论:TILs含量可作为结肠腺癌的独立预后因素，并可作为病理学家常规诊疗的附加工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.